Reviewed, UniProtKB/Swiss-Prot P05106 (ITB3_HUMAN)

Names and origin

Protein names

Recommended name:
Integrin beta-3

Alternative name(s):
Platelet membrane glycoprotein IIIa
Short name=GPIIIa
CD_antigen=CD61

Gene names

Name:	ITGB3
Synonyms:	GP3A

Organism

Homo sapiens (Human) [Complete proteome]

Taxonomic identifier

9606 [NCBI]

Taxonomic lineage

Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo

Protein attributes

Sequence length	788 AA.
Sequence status	Complete.
Sequence processing	The displayed sequence is further processed into a mature form.
Protein existence	Evidence at protein level.

General annotation (Comments)

Function	Integrin alpha-V/beta-3 is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
Subunit structure	Heterodimer of an alpha and a beta subunit. Beta-3 associates with either alpha-IIb or alpha-V. Isoform Beta-3C interacts with FLNB. Interacts with COMP. Interacts with HIV-1 Tat. Ref.17 Ref.18 Ref.21
Subcellular location	Membrane; Single-pass type I membrane protein.
Tissue specificity	Isoform beta-3A and isoform beta-3C are widely expressed. Isoform beta-3A is specifically expressed in osteoblast cells; isoform beta-3C is specifically expressed in prostate and testis.
Post-translational modification	Phosphorylated on tyrosine residues in response to thrombin-induced platelet aggregation. Probably involved in outside-in signaling. A peptide (AA 740-762) is capable of binding GRB2 only when both Tyr-773 and Tyr-785 are phosphorylated. Phosphorylation of Thr-779 inhibits SHC binding. Ref.19 Ref.20 Ref.25 Ref.27
Polymorphism	Position 59 is associated with platelet-specific alloantigen HPA-1 (ZW or PL(A)). HPA-1A/ZW(A)/PL(A1) has Leu-59 and HPA-1B/ZW(B)/PL(A2) has Pro-59. HPA-1A is involved in fetal-maternal alloimmune thromobocytopenia (FMAIT) as well as in neonatal alloimmune thrombocytopenia (NAIT). Position 169 is associated with platelet-specific alloantigen HPA-4 (PEN or YUK). HPA-4A/PEN(A)/YUK(A) has Arg-169 and HPA-4B/PEN(B)/YUK(B) has Gln-169. HPA-4B is involved in neonatal alloimmune thrombocytopenia (NAIT or NATP). Position 433 is associated with platelet-specific alloantigen MO. MO- has Pro-433 and MO+ has Ala-433. MO+ is involved in NAIT. Position 515 is associated with platelet-specific alloantigen CA/TU. CA-/TU- has Arg-515 and CA+/TU+ has Gln-515. CA+ is involved in NAIT. Position 662 is associated with platelet-specific alloantigen SR(A). SR(A)- has Arg-662 and SR(A)+ has Cys-662.
Involvement in disease	Defects in ITGB3 are a cause of Glanzmann thrombasthenia (GT) [MIM:273800]; also known as thrombasthenia of Glanzmann and Naegeli. GT is the most common inherited disease of platelets. It is an autosomal recessive disorder characterized by mucocutaneous bleeding of mild-to-moderate severity and the inability of this integrin to recognize macromolecular or synthetic peptide ligands. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb/beta-3 complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the glycoprotein IIb/beta-3 complex at reduced levels (5-20% controls), have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. The platelets of GT 'variants' have normal or near normal (60-100%) expression of dysfunctional receptors. Ref.36 Ref.37 Ref.38 Ref.39 Ref.40 Ref.41 Ref.42 Ref.43 Ref.44 Ref.45 Ref.48 Ref.50 Ref.51 Ref.52 Ref.53 Ref.54 Ref.55
Sequence similarities	Belongs to the integrin beta chain family. Contains 1 VWFA domain.

Ontologies

Keywords
Biological process	Cell adhesion Host-virus interaction
Cellular component	Membrane
Coding sequence diversity	Alternative splicing Polymorphism
Disease	Disease mutation
Domain	Repeat Signal Transmembrane
Molecular function	Integrin Receptor
PTM	Disulfide bond Glycoprotein Phosphoprotein
Technical term	3D-structure Complete proteome Direct protein sequencing
Gene Ontology (GO)
Biological process	blood coagulation Ref.39 Traceable author statement. Source: ProtInc cell-matrix adhesion Inferred from electronic annotation. Source: InterPro integrin-mediated signaling pathway Inferred from electronic annotation. Source: UniProtKB-KW interspecies interaction between organisms Inferred from electronic annotation. Source: UniProtKB-KW negative regulation of lipid storage Inferred from mutant phenotype. Source: UniProtKB negative regulation of lipid transport Inferred from mutant phenotype. Source: UniProtKB negative regulation of lipoprotein metabolic process Inferred from mutant phenotype. Source: UniProtKB negative regulation of low-density lipoprotein receptor biosynthetic process Inferred from mutant phenotype. Source: UniProtKB negative regulation of macrophage derived foam cell differentiation Inferred from mutant phenotype. Source: UniProtKB
Cellular component	integrin complex Ref.39 Inferred from direct assay. Source: UniProtKB platelet alpha granule membrane Inferred from Experiment. Source: Reactome
Molecular function	identical protein binding Inferred from physical interaction. Source: IntAct receptor activity Inferred from electronic annotation. Source: UniProtKB-KW
Complete GO annotation...

Binary interactions

With	Entry	#Exp.	IntAct	Notes
itself		3	EBI-702847,EBI-702847
	P06935	2	EBI-702847,EBI-981051	From a different organism.
ITGAV	P06756	3	EBI-702847,EBI-298282
TLN1	P54939	1	EBI-702847,EBI-1035421	From a different organism.
Tln1	P26039	1	EBI-702847,EBI-1039593	From a different organism.

Alternative products

This entry describes 3 isoforms produced by alternative splicing. [Align] [Select]

Isoform Beta-3A (identifier: P05106-1)

This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry.

Isoform Beta-3B (identifier: P05106-2)

The sequence of this isoform differs from the canonical sequence as follows:
     768-788: ANNPLYKEATSTFTNITYRGT → VRDGAGRFLKSLV

Isoform Beta-3C (identifier: P05106-3)

The sequence of this isoform differs from the canonical sequence as follows:
     768-788: ANNPLYKEATSTFTNITYRGT → HYAQSLRKWNQPVSIDG

Sequence annotation (Features)

Feature key

Position(s)

Length

Description

Graphical view

Feature identifier

Molecule processing

Signal peptide

1 – 26

26

Potential

Chain

27 – 788

762

Integrin beta-3

PRO_0000016344

Regions

Topological domain

27 – 718

692

Extracellular Potential

Transmembrane

719 – 741

23

Potential

Topological domain

742 – 788

47

Cytoplasmic Potential

Domain

135 – 377

243

VWFA

Repeat

463 – 511

49

I

Repeat

512 – 553

42

II

Repeat

554 – 592

39

III

Repeat

593 – 629

37

IV

Region

463 – 629

167

Cysteine-rich tandem repeats

Amino acid modifications

Modified residue

773

1

Phosphotyrosine Ref.19 Ref.25 Ref.27

Modified residue

779

1

Phosphothreonine; by PDPK1 and PKB/AKT1; in vitro Ref.20

Modified residue

785

1

Phosphotyrosine Ref.19 Ref.25

Glycosylation

125

1

N-linked (GlcNAc...) Ref.23 Ref.24

Glycosylation

346

1

N-linked (GlcNAc...) Potential

Glycosylation

397

1

N-linked (GlcNAc...) Potential

Glycosylation

478

1

N-linked (GlcNAc...)

Glycosylation

585

1

N-linked (GlcNAc...) Potential

Glycosylation

680

1

N-linked (GlcNAc...) Ref.26

Disulfide bond

31 ↔ 461

Ref.16

Disulfide bond

39 ↔ 49

Ref.16

Disulfide bond

42 ↔ 75

Ref.16

Disulfide bond

52 ↔ 64

Ref.16

Disulfide bond

203 ↔ 210

Ref.16

Disulfide bond

258 ↔ 299

Ref.16

Disulfide bond

400 ↔ 412

Ref.16

Disulfide bond

432 ↔ 681

Ref.16

Disulfide bond

459 ↔ 463

Ref.16

Disulfide bond

474 ↔ 486

Probable

Disulfide bond

483 ↔ 521

Probable

Disulfide bond

488 ↔ 497

Probable

Disulfide bond

499 ↔ 512

Probable

Disulfide bond

527 ↔ 532

Probable

Disulfide bond

529 ↔ 562

Probable

Disulfide bond

534 ↔ 547

Probable

Disulfide bond

549 ↔ 554

Ref.16

Disulfide bond

568 ↔ 573

Probable

Disulfide bond

570 ↔ 601

Probable

Disulfide bond

575 ↔ 584

Probable

Disulfide bond

586 ↔ 593

Probable

Disulfide bond

607 ↔ 612

Probable

Disulfide bond

609 ↔ 657

Probable

Disulfide bond

614 ↔ 624

Probable

Disulfide bond

627 ↔ 630

Probable

Disulfide bond

634 ↔ 643

Probable

Disulfide bond

640 ↔ 713

Probable

Disulfide bond

661 ↔ 689

Ref.16

Natural variations

Alternative sequence

768 – 788

21

ANNPL…TYRGT → VRDGAGRFLKSLV in isoform Beta-3B.

VSP_002745

Alternative sequence

768 – 788

21

ANNPL…TYRGT → HYAQSLRKWNQPVSIDG in isoform Beta-3C.

VSP_002746

Natural variant

59

1

L → P in alloantigen HPA-1B. dbSNP rs5918. Ref.12 Ref.31 Ref.46

VAR_003993

Natural variant

66

1

L → R: dbSNP rs36080296. Ref.12

VAR_049633

Natural variant

119

1

R → W in GT. Ref.51

VAR_030473

Natural variant

141

1

Y → C in GT. Ref.55

VAR_030474

Natural variant

143

1

L → W in GT. Ref.41

VAR_010649

Natural variant

145

1

D → N in GT. Ref.42

VAR_030475

Natural variant

145

1

D → Y in GT; type B. Ref.36

VAR_003998

Natural variant

150

1

M → V in GT; may confer constitutive activity to the alpha-IIb/(mutated)beta-3 receptor. Ref.53

VAR_030476

Natural variant

166

1

T → I Associated with neonatal thrombocytopenia; alloantigen Duv(a+); does not affect significantly the integrin function. Ref.49

VAR_030477

Natural variant

169

1

R → Q in alloantigen HPA-4B. dbSNP rs5917. Ref.46 Ref.32

VAR_003994

Natural variant

188

1

S → L in GT; type II. Ref.44

VAR_010651

Natural variant

222

1

L → P in GT; variant form. Ref.50

VAR_030478

Natural variant

240

1

R → Q in GT; type B. Ref.37

VAR_003999

Natural variant

240

1

R → W in GT; variant Strasbourg-1. Ref.38

VAR_004000

Natural variant

242

1

R → Q in GT. Ref.42

VAR_030479

Natural variant

243

1

D → V in GT. Ref.51

VAR_030480

Natural variant

288

1

L → P in GT. Ref.42

VAR_030481

Natural variant

306

1

H → P in GT. dbSNP rs13306476. Ref.43 Ref.54

VAR_004001

Natural variant

321

1

M → L in GT. Ref.55

VAR_030482

Natural variant

330

1

I → N in GT; not expressed on the surface and absent inside the transfected cells. Ref.54

VAR_030483

Natural variant

400

1

C → Y in GT. Ref.40

VAR_004002

Natural variant

433

1

P → A in alloantigen MO(+); in a case of neonatal alloimmune thrombocytopenia. Ref.33

VAR_003995

Natural variant

453

1

V → I: dbSNP rs5921. Ref.46

VAR_014178

Natural variant

515

1

R → Q in alloantigen CA(+)/TU(+). dbSNP rs13306487. Ref.34

VAR_003996

Natural variant

532

1

C → Y in GT. Ref.52

VAR_030484

Natural variant

568

1

C → R in GT; type I. Ref.45

VAR_010671

Natural variant

586

1

C → F in GT. Ref.43

VAR_004003

Natural variant

586

1

C → R in GT; gain-of-function mutation; constitutively binds ligand-induced binding sites antibodies and the fibrinogen-mimetic antibody PAC-1. Ref.48

VAR_030485

Natural variant

598

1

G → S in GT. Ref.43

VAR_004004

Natural variant

601

1

C → R in GT. Ref.51

VAR_030486

Natural variant

605

1

G → S in GT; type II. Ref.43

VAR_010672

Natural variant

662

1

R → C in alloantigen SR(A). Ref.35

VAR_003997

Natural variant

778

1

S → P in GT; variant Strasbourg-1. Ref.39

VAR_004005

Experimental info

Sequence conflict

12

1

A → V in AAA52589. Ref.1

Sequence conflict

12

1

A → V in AAA35927. Ref.3

Sequence conflict

151

1

K → P in AAA67537. Ref.10

Sequence conflict

151

1

K → P in AAB23689. Ref.13

Sequence conflict

205

1

D → EY in AAA67537. Ref.10

Sequence conflict

649 – 653

5

GALHD → EPYMT in AAA52589. Ref.1

Sequence conflict

649 – 653

5

GALHD → EPYMT in AAA60122. Ref.2

Sequence conflict

649 – 653

5

GALHD → EPYMT in AAB71380. Ref.4

Sequence conflict

716

1

G → H Ref.7

Sequence conflict

737 – 741

5

ALLIW → PCSSG in AAA67537. Ref.10

Secondary structure

1

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

788

Helix Strand Turn

Details...

Turn

30 – 34

5

Helix

39 – 43

5

Beta strand

49 – 52

4

Beta strand

55 – 57

3

Beta strand

63 – 66

4

Helix

67 – 72

6

Helix

77 – 79

3

Beta strand

102 – 104

3

Beta strand

112 – 118

7

Beta strand

123 – 126

4

Beta strand

129 – 131

3

Beta strand

138 – 145

8

Helix

148 – 150

3

Turn

151 – 157

7

Helix

162 – 169

8

Beta strand

173 – 182

10

Turn

188 – 192

5

Beta strand

194 – 196

3

Helix

197 – 199

3

Beta strand

205 – 207

3

Beta strand

215 – 217

3

Beta strand

222 – 224

3

Helix

228 – 234

7

Beta strand

242 – 246

5

Helix

249 – 257

9

Helix

259 – 262

4

Beta strand

266 – 278

13

Helix

285 – 287

3

Turn

288 – 290

3

Helix

308 – 311

4

Helix

318 – 327

10

Beta strand

330 – 337

8

Helix

338 – 340

3

Helix

341 – 348

8

Beta strand

355 – 359

5

Helix

364 – 366

3

Helix

367 – 377

11

Beta strand

383 – 386

4

Beta strand

390 – 392

3

Beta strand

420 – 422

3

Beta strand

425 – 431

7

Beta strand

439 – 444

6

Beta strand

452 – 457

6

Beta strand

579 – 584

6

Helix

600 – 603

4

Beta strand

605 – 608

4

Beta strand

611 – 614

4

Helix

633 – 635

3

Helix

638 – 641

4

Turn

642 – 646

5

Turn

650 – 652

3

Beta strand

653 – 655

3

Turn

658 – 660

3

Beta strand

665 – 671

7

Beta strand

676 – 680

5

Beta strand

693 – 695

3

Turn

699 – 701

3

Beta strand

705 – 710

6

Turn

743 – 759

17

Helix

771 – 774

4

Sequences

	Sequence		Length	Mass (Da)
	Isoform Beta-3A [UniParc]. Last modified February 6, 2007. Version 2. Checksum: F246623608E05F9E	FASTA	788	87,058
	10 20 30 40 50 60 MRARPRPRPL WATVLALGAL AGVGVGGPNI CTTRGVSSCQ QCLAVSPMCA WCSDEALPLG 70 80 90 100 110 120 SPRCDLKENL LKDNCAPESI EFPVSEARVL EDRPLSDKGS GDSSQVTQVS PQRIALRLRP 130 140 150 160 170 180 DDSKNFSIQV RQVEDYPVDI YYLMDLSYSM KDDLWSIQNL GTKLATQMRK LTSNLRIGFG 190 200 210 220 230 240 AFVDKPVSPY MYISPPEALE NPCYDMKTTC LPMFGYKHVL TLTDQVTRFN EEVKKQSVSR 250 260 270 280 290 300 NRDAPEGGFD AIMQATVCDE KIGWRNDASH LLVFTTDAKT HIALDGRLAG IVQPNDGQCH 310 320 330 340 350 360 VGSDNHYSAS TTMDYPSLGL MTEKLSQKNI NLIFAVTENV VNLYQNYSEL IPGTTVGVLS 370 380 390 400 410 420 MDSSNVLQLI VDAYGKIRSK VELEVRDLPE ELSLSFNATC LNNEVIPGLK SCMGLKIGDT 430 440 450 460 470 480 VSFSIEAKVR GCPQEKEKSF TIKPVGFKDS LIVQVTFDCD CACQAQAEPN SHRCNNGNGT 490 500 510 520 530 540 FECGVCRCGP GWLGSQCECS EEDYRPSQQD ECSPREGQPV CSQRGECLCG QCVCHSSDFG 550 560 570 580 590 600 KITGKYCECD DFSCVRYKGE MCSGHGQCSC GDCLCDSDWT GYYCNCTTRT DTCMSSNGLL 610 620 630 640 650 660 CSGRGKCECG SCVCIQPGSY GDTCEKCPTC PDACTFKKEC VECKKFDRGA LHDENTCNRY 670 680 690 700 710 720 CRDEIESVKE LKDTGKDAVN CTYKNEDDCV VRFQYYEDSS GKSILYVVEE PECPKGPDIL 730 740 750 760 770 780 VVLLSVMGAI LLIGLAALLI WKLLITIHDR KEFAKFEEER ARAKWDTANN PLYKEATSTF TNITYRGT
	Isoform Beta-3B. Checksum: C21A1B7814080CD7	FASTA	780	86,113
	10 20 30 40 50 60 MRARPRPRPL WATVLALGAL AGVGVGGPNI CTTRGVSSCQ QCLAVSPMCA WCSDEALPLG 70 80 90 100 110 120 SPRCDLKENL LKDNCAPESI EFPVSEARVL EDRPLSDKGS GDSSQVTQVS PQRIALRLRP 130 140 150 160 170 180 DDSKNFSIQV RQVEDYPVDI YYLMDLSYSM KDDLWSIQNL GTKLATQMRK LTSNLRIGFG 190 200 210 220 230 240 AFVDKPVSPY MYISPPEALE NPCYDMKTTC LPMFGYKHVL TLTDQVTRFN EEVKKQSVSR 250 260 270 280 290 300 NRDAPEGGFD AIMQATVCDE KIGWRNDASH LLVFTTDAKT HIALDGRLAG IVQPNDGQCH 310 320 330 340 350 360 VGSDNHYSAS TTMDYPSLGL MTEKLSQKNI NLIFAVTENV VNLYQNYSEL IPGTTVGVLS 370 380 390 400 410 420 MDSSNVLQLI VDAYGKIRSK VELEVRDLPE ELSLSFNATC LNNEVIPGLK SCMGLKIGDT 430 440 450 460 470 480 VSFSIEAKVR GCPQEKEKSF TIKPVGFKDS LIVQVTFDCD CACQAQAEPN SHRCNNGNGT 490 500 510 520 530 540 FECGVCRCGP GWLGSQCECS EEDYRPSQQD ECSPREGQPV CSQRGECLCG QCVCHSSDFG 550 560 570 580 590 600 KITGKYCECD DFSCVRYKGE MCSGHGQCSC GDCLCDSDWT GYYCNCTTRT DTCMSSNGLL 610 620 630 640 650 660 CSGRGKCECG SCVCIQPGSY GDTCEKCPTC PDACTFKKEC VECKKFDRGA LHDENTCNRY 670 680 690 700 710 720 CRDEIESVKE LKDTGKDAVN CTYKNEDDCV VRFQYYEDSS GKSILYVVEE PECPKGPDIL 730 740 750 760 770 780 VVLLSVMGAI LLIGLAALLI WKLLITIHDR KEFAKFEEER ARAKWDTVRD GAGRFLKSLV
	Isoform Beta-3C. Checksum: B8A9F2A7F3C39247	FASTA	784	86,694
	10 20 30 40 50 60 MRARPRPRPL WATVLALGAL AGVGVGGPNI CTTRGVSSCQ QCLAVSPMCA WCSDEALPLG 70 80 90 100 110 120 SPRCDLKENL LKDNCAPESI EFPVSEARVL EDRPLSDKGS GDSSQVTQVS PQRIALRLRP 130 140 150 160 170 180 DDSKNFSIQV RQVEDYPVDI YYLMDLSYSM KDDLWSIQNL GTKLATQMRK LTSNLRIGFG 190 200 210 220 230 240 AFVDKPVSPY MYISPPEALE NPCYDMKTTC LPMFGYKHVL TLTDQVTRFN EEVKKQSVSR 250 260 270 280 290 300 NRDAPEGGFD AIMQATVCDE KIGWRNDASH LLVFTTDAKT HIALDGRLAG IVQPNDGQCH 310 320 330 340 350 360 VGSDNHYSAS TTMDYPSLGL MTEKLSQKNI NLIFAVTENV VNLYQNYSEL IPGTTVGVLS 370 380 390 400 410 420 MDSSNVLQLI VDAYGKIRSK VELEVRDLPE ELSLSFNATC LNNEVIPGLK SCMGLKIGDT 430 440 450 460 470 480 VSFSIEAKVR GCPQEKEKSF TIKPVGFKDS LIVQVTFDCD CACQAQAEPN SHRCNNGNGT 490 500 510 520 530 540 FECGVCRCGP GWLGSQCECS EEDYRPSQQD ECSPREGQPV CSQRGECLCG QCVCHSSDFG 550 560 570 580 590 600 KITGKYCECD DFSCVRYKGE MCSGHGQCSC GDCLCDSDWT GYYCNCTTRT DTCMSSNGLL 610 620 630 640 650 660 CSGRGKCECG SCVCIQPGSY GDTCEKCPTC PDACTFKKEC VECKKFDRGA LHDENTCNRY 670 680 690 700 710 720 CRDEIESVKE LKDTGKDAVN CTYKNEDDCV VRFQYYEDSS GKSILYVVEE PECPKGPDIL 730 740 750 760 770 780 VVLLSVMGAI LLIGLAALLI WKLLITIHDR KEFAKFEEER ARAKWDTHYA QSLRKWNQPV SIDG

References

	« Hide 'large scale' referencesShow 'large scale' references »
[1]	"Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone. Identity with platelet glycoprotein IIIa and similarity to 'integrin'." Fitzgerald L.A., Steiner B., Rall S.C. Jr., Lo S., Phillips D.R. J. Biol. Chem. 262:3936-3939(1987) [PubMed: 3494014] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-3A).
[2]	"Structure of platelet glycoprotein IIIa. A common subunit for two different membrane receptors." Zimrin A.B., Eisman R., Vilaire G., Schwartz E., Bennett J.S., Poncz M. J. Clin. Invest. 81:1470-1475(1988) [PubMed: 2452834] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-3A).
[3]	"GPIIb and GPIIIa amino acid sequences deduced from human megakaryocyte cDNAs." Frachet P., Uzan G., Thevenon D., Denarier E., Prandini M.H., Marguerie G. Mol. Biol. Rep. 14:27-33(1990) [PubMed: 2345548] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-3A).
[4]	"Cloning and characterization of a novel integrin beta3 subunit." Kumar C.S., James I.E., Wong A., Mwangi V., Feild J.A., Nuthulaganti P., Connor J.R., Eichman C., Ali F., Hwang S.M., Rieman D.J., Drake F.H., Gowen M. J. Biol. Chem. 272:16390-16397(1997) [PubMed: 9195946] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-3C). Tissue: Osteoclastoma.
[5]	"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed: 15489334] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BETA-3A).
[6]	"Isolation and characterization of a TATA-less promoter for the human beta 3 integrin gene." Villa-Garcia M., Li L., Riely G., Bray P.F. Blood 83:668-676(1994) [PubMed: 8298129] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-26. Tissue: Blood.
[7]	"Cloning of glycoprotein IIIa cDNA from human erythroleukemia cells and localization of the gene to chromosome 17." Rosa J.P., Bray P.F., Gayet O., Johnston G.I., Cook R.G., Jackson K.W., Shuman M.A., McEver R.P. Blood 72:593-600(1988) [PubMed: 3165296] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 11-788. Tissue: Erythroleukemia.
[8]	"Separation of important new platelet glycoproteins (GPIa, GPIc, GPIc*, GPIIa and GMP-140) by F.P.L.C. Characterization by monoclonal antibodies and gas-phase sequencing." Catimel B., Parmentier S., Leung L.L., McGregor J.L. Biochem. J. 279:419-425(1991) [PubMed: 1953640] [Abstract] Cited for: PROTEIN SEQUENCE OF 27-37. Tissue: Platelet.
[9]	"Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides." Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R., Vandekerckhove J. Nat. Biotechnol. 21:566-569(2003) [PubMed: 12665801] [Abstract] Cited for: PROTEIN SEQUENCE OF 27-34. Tissue: Platelet.
[10]	"The genomic organization of platelet glycoprotein IIIa." Zimrin A.B., Gidwitz S., Lord S., Schwartz E., Bennett J.S., White G.C. II, Poncz M. J. Biol. Chem. 265:8590-8595(1990) [PubMed: 2341395] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 28-788.
[11]	"Characterization of the human platelet glycoprotein IIIa gene. Comparison with the fibronectin receptor beta-subunit gene." Lanza F., Kieffer N., Phillips D.R., Fitzgerald L.A. J. Biol. Chem. 265:18098-18103(1990) [PubMed: 2145280] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 28-788.
[12]	"A new exon II polymorphism in the platelet glycoprotein IIIa." Pascual C., Balas A., Garcia-Sanchez F., Rodriguez de la Rua A., Vicario J.L. Submitted (DEC-1993) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 56-120, VARIANTS PRO-59 AND ARG-66. Tissue: Blood.
[13]	"The gene organization of the human beta 7 subunit, the common beta subunit of the leukocyte integrins HML-1 and LPAM-1." Jiang W.-M., Jenkins D., Yuan Q., Leung E., Choo K.H., Watson J.D., Krissansen G.W. Int. Immunol. 4:1031-1040(1992) [PubMed: 1382574] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 122-204.
[14]	"Purification and partial amino acid sequence of human platelet membrane glycoproteins IIb and IIIa." Hiraiwa A., Matsukage A., Shiku H., Takahashi T., Naito K., Yamada K. Blood 69:560-564(1987) [PubMed: 3801670] [Abstract] Cited for: PROTEIN SEQUENCE OF 218-234 AND 439-443.
[15]	"An alternative cytoplasmic domain of the integrin beta 3 subunit." Van Kuppevelt T.H.M.S.M., Languino L.R., Gailit J.O., Suzuki S., Ruoslahti E. Proc. Natl. Acad. Sci. U.S.A. 86:5415-5418(1989) [PubMed: 2787511] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 707-788 (ISOFORM BETA-3B). Tissue: Placenta.
[16]	"Assignment of disulphide bonds in human platelet GPIIIa. A disulphide pattern for the beta-subunits of the integrin family." Calvete J.J., Henschen A., Gonzalez-Rodriguez J. Biochem. J. 274:63-71(1991) [PubMed: 2001252] [Abstract] Cited for: PARTIAL PROTEIN SEQUENCE, DISULFIDE BONDS.
[17]	"The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor." Barillari G., Sgadari C., Fiorelli V., Samaniego F., Colombini S., Manzari V., Modesti A., Nair B.C., Cafaro A., Stuerzl M., Ensoli B. Blood 94:663-672(1999) [PubMed: 10397733] [Abstract] Cited for: INTERACTION WITH HIV-1 TAT.
[18]	"Different splice variants of filamin-B affect myogenesis, subcellular distribution, and determine binding to integrin (beta) subunits." van Der Flier A., Kuikman I., Kramer D., Geerts D., Kreft M., Takafuta T., Shapiro S.S., Sonnenberg A. J. Cell Biol. 156:361-376(2002) [PubMed: 11807098] [Abstract] Cited for: INTERACTION WITH FLNB. Tissue: Keratinocyte and Skeletal muscle.
[19]	"Outside-in integrin signal transduction. Alpha IIb beta 3-(GP IIb IIIa) tyrosine phosphorylation induced by platelet aggregation." Law D.A., Nannizzi-Alaimo L., Phillips D.R. J. Biol. Chem. 271:10811-10815(1996) [PubMed: 8631894] [Abstract] Cited for: PHOSPHORYLATION AT TYR-773 AND TYR-785 (ISOFORM BETA-3A).
[20]	"Threonine phosphorylation of the beta 3 integrin cytoplasmic tail, at a site recognized by PDK1 and Akt/PKB in vitro, regulates Shc binding." Kirk R.I., Sanderson M.R., Lerea K.M. J. Biol. Chem. 275:30901-30906(2000) [PubMed: 10896934] [Abstract] Cited for: PHOSPHORYLATION AT THR-779.
[21]	"Cartilage oligomeric matrix protein/thrombospondin 5 supports chondrocyte attachment through interaction with integrins." Chen F.-H., Thomas A.O., Hecht J.T., Goldring M.B., Lawler J. J. Biol. Chem. 280:32655-32661(2005) [PubMed: 16051604] [Abstract] Cited for: INTERACTION WITH COMP.
[22]	"Naturally processed peptides spanning the HPA-1a polymorphism are efficiently generated and displayed from platelet glycoprotein by HLA-DRB3*0101-positive antigen-presenting cells." Anani Sarab G., Moss M., Barker R.N., Urbaniak S.J. Blood 114:1954-1957(2009) [PubMed: 19494351] [Abstract] Cited for: IDENTIFICATION OF ALLOANTIGEN HPA-1A BY MASS SPECTROMETRY, ASSOCIATION TO ALLELE HLA-DRB3*0101.
[23]	"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry." Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., Smith R.D. J. Proteome Res. 4:2070-2080(2005) [PubMed: 16335952] [Abstract] Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-125, MASS SPECTROMETRY. Tissue: Plasma.
[24]	"Elucidation of N-glycosylation sites on human platelet proteins: a glycoproteomic approach." Lewandrowski U., Moebius J., Walter U., Sickmann A. Mol. Cell. Proteomics 5:226-233(2006) [PubMed: 16263699] [Abstract] Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-125, MASS SPECTROMETRY. Tissue: Platelet.
[25]	"Phosphoproteome of resting human platelets." Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., Schuetz C., Walter U., Gambaryan S., Sickmann A. J. Proteome Res. 7:526-534(2008) [PubMed: 18088087] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-773 AND TYR-785, MASS SPECTROMETRY. Tissue: Platelet.
[26]	"Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry." Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H. J. Proteome Res. 8:651-661(2009) [PubMed: 19159218] [Abstract] Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-680, MASS SPECTROMETRY. Tissue: Liver.
[27]	"Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions." Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., Rodionov V., Han D.K. Sci. Signal. 2:RA46-RA46(2009) [PubMed: 19690332] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-773, MASS SPECTROMETRY. Tissue: T-cell.
[28]	"Crystal structure of the extracellular segment of integrin alpha Vbeta3." Xiong J.P., Stehle T., Diefenbach B., Zhang R., Dunker R., Scott D.L., Joachimiak A., Goodman S.L., Arnaout M.A. Science 294:339-345(2001) [PubMed: 11546839] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 27-718.
[29]	"Crystallographic structure of the human leukocyte antigen DRA, DRB3*0101: models of a directional alloimmune response and autoimmunity." Parry C.S., Gorski J., Stern L.J. J. Mol. Biol. 371:435-446(2007) [PubMed: 17583734] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 50-61 (ALLOANTIGEN HPA-1A) IN COMPLEX WITH HLA-DRA/HLA-DRB3 HETERODIMER.
[30]	"Inherited diseases of platelet glycoproteins: considerations for rapid molecular characterization." Bray P.F. Thromb. Haemost. 72:492-502(1994) [PubMed: 7878622] [Abstract] Cited for: REVIEW ON GT VARIANTS.
[31]	"The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing." Newman P.J., Derbes R.S., Aster R.H. J. Clin. Invest. 83:1778-1781(1989) [PubMed: 2565345] [Abstract] Cited for: VARIANT HPA-1B PRO-59, DESCRIPTION OF ALLOANTIGEN SYSTEM PL(A).
[32]	"An amino acid polymorphism within the RGD binding domain of platelet membrane glycoprotein IIIa is responsible for the formation of the Pena/Penb alloantigen system." Wang R., Furihata K., McFarland J.G., Friedman K., Aster R.H., Newman P.J. J. Clin. Invest. 90:2038-2043(1992) [PubMed: 1430225] [Abstract] Cited for: VARIANT HPA-4B GLN-169, DESCRIPTION OF ALLOANTIGEN SYSTEM PEN.
[33]	"Single point mutation in human glycoprotein IIIa is associated with a new platelet-specific alloantigen (Mo) involved in neonatal alloimmune thrombocytopenia." Kuijpers R.W.A.M., Simsek S., Faber N.M., Goldschmeding R., van Wermerkerken R.K.V., von Dem Borne A.E.G.K. Blood 81:70-76(1993) [PubMed: 8093349] [Abstract] Cited for: VARIANT MO(+) ALA-433.
[34]	"Amino acid 489 is encoded by a mutational 'hot spot' on the beta 3 integrin chain: the CA/TU human platelet alloantigen system." Wang R., McFarland J.G., Kekomaki R., Newman P.J. Blood 82:3386-3391(1993) [PubMed: 7694683] [Abstract] Cited for: VARIANT CA(+)/TU(+) GLN-515, DESCRIPTION OF ALLOANTIGEN SYSTEM CA/TU.
[35]	"A point mutation leads to an unpaired cysteine residue and a molecular weight polymorphism of a functional platelet beta 3 integrin subunit. The Sra alloantigen system of GPIIIa." Santoso S., Kalb R., Kroll H., Walka M., Kiefel V., Mueller-Eckhardt C., Newman P.J. J. Biol. Chem. 269:8439-8444(1994) [PubMed: 8132570] [Abstract] Cited for: VARIANT SR(A) CYS-662, DESCRIPTION OF ALLOANTIGEN SYSTEM SR(A).
[36]	"A beta 3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation." Loftus J.C., O'Toole T.E., Plow E.F., Glass A., Frelinger A.L. III, Ginsberg M.H. Science 249:915-918(1990) [PubMed: 2392682] [Abstract] Cited for: VARIANT GT TYR-145.
[37]	"A spontaneous mutation of integrin alpha IIb beta 3 (platelet glycoprotein IIb-IIIa) helps define a ligand binding site." Bajt M.L., Ginsberg M.H., Frelinger A.L. III, Berndt M.C., Loftus J.C. J. Biol. Chem. 267:3789-3794(1992) [PubMed: 1371279] [Abstract] Cited for: VARIANT GT GLN-240.
[38]	"A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg-->214Trp mutation." Lanza F., Stierle A., Fournier D., Morales M., Andre G., Nurden A.T., Cazenave J.-P. J. Clin. Invest. 89:1995-2004(1992) [PubMed: 1602006] [Abstract] Cited for: VARIANT GT TRP-240.
[39]	"Ser-752-->Pro mutation in the cytoplasmic domain of integrin beta 3 subunit and defective activation of platelet integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia." Chen Y.-P., Djaffar I., Pidard D., Steiner B., Cieutat A.-M., Caen J.P., Rosa J.-P. Proc. Natl. Acad. Sci. U.S.A. 89:10169-10173(1992) [PubMed: 1438206] [Abstract] Cited for: VARIANT GT PRO-778.
[40]	"A Cys374Tyr homozygous mutation of platelet glycoprotein IIIa (beta 3) in a Chinese patient with Glanzmann's thrombasthenia." Grimaldi C.M., Chen F., Scudder L.E., Coller B.S., French D.L. Blood 88:1666-1675(1996) [PubMed: 8781422] [Abstract] Cited for: VARIANT GT TYR-400.
[41]	"A Leu117-->Trp mutation within the RGD-peptide cross-linking region of beta3 results in Glanzmann thrombasthenia by preventing alphaIIb beta3 export to the platelet surface." Basani R.B., Brown D.L., Vilaire G., Bennett J.S., Poncz M. Blood 90:3082-3088(1997) [PubMed: 9376589] [Abstract] Cited for: VARIANT GT TRP-143.
[42]	"Hematologically important mutations: Glanzmann thrombasthenia." French D.L., Coller B.S. Blood Cells Mol. Dis. 23:39-51(1997) [PubMed: 9215749] [Abstract] Cited for: VARIANTS GT ASN-145; GLN-242 AND PRO-288.
[43]	"Three novel integrin beta3 subunit missense mutations (H280P, C560F, and G579S) in thrombasthenia, including one (H280P) prevalent in Japanese patients." Ambo H., Kamata T., Handa M., Taki M., Kuwajima M., Kawai Y., Oda A., Murata M., Takada Y., Watanabe K., Ikeda Y. Biochem. Biophys. Res. Commun. 251:763-768(1998) [PubMed: 9790984] [Abstract] Cited for: VARIANTS GT PRO-306; PHE-586; SER-598 AND SER-605.
[44]	"A Ser162-->Leu mutation within glycoprotein (GP) IIIa (integrin beta3) results in an unstable alphaIIbbeta3 complex that retains partial function in a novel form of type II Glanzmann thrombasthenia." Jackson D.E., White M.M., Jennings L.K., Newman P.J. Thromb. Haemost. 80:42-48(1998) [PubMed: 9684783] [Abstract] Cited for: VARIANT GT LEU-188.
[45]	"Homozygous Cys542-->Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann's thrombasthenia." Ruan J., Schmugge M., Clemetson K.J., Cazes E., Combrie R., Bourre F., Nurden A.T. Br. J. Haematol. 105:523-531(1999) [PubMed: 10233432] [Abstract] Cited for: VARIANT GT ARG-568.
[46]	"Characterization of single-nucleotide polymorphisms in coding regions of human genes." Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., Lander E.S. Nat. Genet. 22:231-238(1999) [PubMed: 10391209] [Abstract] Cited for: VARIANTS PRO-59; GLN-169 AND ILE-453.
[47]	Erratum Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., Lander E.S. Nat. Genet. 23:373-373(1999)
[48]	"A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (alphaIIbbeta3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype." Ruiz C., Liu C.-Y., Sun Q.-H., Sigaud-Fiks M., Fressinaud E., Muller J.-Y., Nurden P., Nurden A.T., Newman P.J., Valentin N. Blood 98:2432-2441(2001) [PubMed: 11588040] [Abstract] Cited for: VARIANT GT ARG-586, CHARACTERIZATION OF VARIANT GT ARG-586.
[49]	"A new platelet polymorphism Duv(a+), localized within the RGD binding domain of glycoprotein IIIa, is associated with neonatal thrombocytopenia." Jallu V., Meunier M., Brement M., Kaplan C. Blood 99:4449-4456(2002) [PubMed: 12036875] [Abstract] Cited for: VARIANT ILE-166, CHARACTERIZATION OF VARIANT ILE-166.
[50]	"A novel 196Leu to Pro substitution in the beta3 subunit of the alphaIIbbeta3 integrin in a patient with a variant form of Glanzmann thrombasthenia." Nurden A.T., Ruan J., Pasquet J.-M., Gauthier B., Combrie R., Kunicki T., Nurden P. Platelets 13:101-111(2002) [PubMed: 11897046] [Abstract] Cited for: VARIANT GT PRO-222.
[51]	"Glanzmann's thrombasthenia: identification of 19 new mutations in 30 patients." D'Andrea G., Colaizzo D., Vecchione G., Grandone E., Di Minno G., Margaglione M. Thromb. Haemost. 87:1034-1042(2002) [PubMed: 12083483] [Abstract] Cited for: VARIANTS GT TRP-119; VAL-243 AND ARG-601.
[52]	"Two new beta3 integrin mutations in Indian patients with Glanzmann thrombasthenia: localization of mutations affecting cysteine residues in integrin beta3." Nair S., Li J., Mitchell W.B., Mohanty D., Coller B.S., French D.L. Thromb. Haemost. 88:503-509(2002) [PubMed: 12353082] [Abstract] Cited for: VARIANT GT TYR-532.
[53]	"A variant thrombasthenic phenotype associated with compound heterozygosity of integrin beta3-subunit: (Met124Val)beta3 alters the subunit dimerization rendering a decreased number of constitutive active alphaIIbbeta3 receptors." Gonzalez-Manchon C., Butta N., Larrucea S., Arias-Salgado E.G., Alonso S., Lopez A., Parrilla R. Thromb. Haemost. 92:1377-1386(2004) [PubMed: 15583747] [Abstract] Cited for: VARIANT GT VAL-150, CHARACTERIZATION OF VARIANT GT VAL-150.
[54]	"Double heterozygosity for a novel missense mutation of Ile304 to Asn in addition to the missense mutation His280 to Pro in the integrin beta3 gene as a cause of the absence of platelet alphaIIbbeta3 in Glanzmann's thrombasthenia." Tanaka S., Hayashi T., Yoshimura K., Nakayama M., Fujita T., Amano T., Tani Y. J. Thromb. Haemost. 3:68-73(2005) [PubMed: 15634267] [Abstract] Cited for: VARIANTS GT PRO-306 AND ASN-330, CHARACTERIZATION OF VARIANT GT ASN-330.
[55]	"Mutations in GPIIIa molecule as a cause for Glanzmann thrombasthenia in Indian patients." Nair S., Ghosh K., Shetty S., Mohanty D. J. Thromb. Haemost. 3:482-488(2005) [PubMed: 15748237] [Abstract] Cited for: VARIANTS GT CYS-141 AND LEU-321.
+	Additional computationally mapped references.

Web resources

GeneReviews

SHMPD

The Singapore human mutation and polymorphism database

Cross-references

Sequence databases

EMBL
GenBank
DDBJ

J02703 mRNA. Translation: AAA52589.1.
M20311 mRNA. Translation: AAA60122.1.
M35999 mRNA. Translation: AAA35927.1.
U95204 mRNA. Translation: AAB71380.1.
BC127666 mRNA. Translation: AAI27667.1.
BC127667 mRNA. Translation: AAI27668.1.
L28832 Genomic DNA. Translation: AAA20880.2.
M32686 , M32667, M32672, M32673, M32674, M32675, M32680, M32681, M32682, M32685 Genomic DNA. Translation: AAA67537.1.
M57494 , M57481, M57482, M57483, M57484, M57485, M57486, M57487, M57488, M57489, M57490, M57491, M57492, M57493 Genomic DNA. Translation: AAA52600.1.
U03881 Genomic DNA. Translation: AAA16076.1.
S49379 Genomic DNA. Translation: AAB23689.2.
M25108 mRNA. Translation: AAA36121.1.

IPI

IPI00220350.
IPI00220351.
IPI00303283.

PIR

A26547.
A60798.
B36268.
I77349.
S14324.

RefSeq

NP_000203.2.

UniGene

Hs.218040

3D structure databases

PDBe
RCSB PDB
PDBj

Entry	Method	Resolution (Å)	Chain	Positions	PDBsum
1JV2	X-ray	3.10	B	27-718	[»]
1KUP	NMR	-	B	742-766	[»]
1KUZ	NMR	-	B	742-766	[»]
1L5G	X-ray	3.20	B	27-718	[»]
1M1X	X-ray	3.30	B	27-718	[»]
1M8O	NMR	-	B	742-788	[»]
1MK7	X-ray	2.20	A/C	765-775	[»]
1MK9	X-ray	2.80	A/C/E/G	765-776	[»]
1RN0	model	-	B	135-378	[»]
1S4X	NMR	-	A	742-788	[»]
1TYE	X-ray	2.90	B/D/F	27-466	[»]
1U8C	X-ray	3.10	B	27-718	[»]
2INI	model	-	B	81-460	[»]
			B	558-716	[»]
2K9J	NMR	-	B	711-753	[»]
2KNC	NMR	-	B	715-788	[»]
2Q6W	X-ray	2.25	C/F	50-61	[»]
2RMZ	NMR	-	A	711-753	[»]
2RN0	NMR	-	A	711-753	[»]
2VC2	X-ray	3.10	B	27-487	[»]
2VDK	X-ray	2.80	B	27-487	[»]
2VDL	X-ray	2.75	B	27-487	[»]
2VDM	X-ray	2.90	B	27-487	[»]
2VDN	X-ray	2.90	B	27-487	[»]
2VDO	X-ray	2.51	B	27-487	[»]
2VDP	X-ray	2.80	B	27-487	[»]
2VDQ	X-ray	2.59	B	27-487	[»]
2VDR	X-ray	2.40	B	27-487	[»]
3FCS	X-ray	2.55	B/D	27-716	[»]
3FCU	X-ray	2.90	B/D/F	27-487	[»]
3IJE	X-ray	2.90	B	27-721	[»]

SMR

P05106. Positions 711-753.

ModBase

Search...

Protein-protein interaction databases

DIP

DIP-304N.

IntAct

P05106. 10 interactions.

STRING

P05106.

PTM databases

PhosphoSite

P05106.

Proteomic databases

PRIDE

P05106.

Genome annotation databases

Ensembl

ENST00000262017; ENSP00000262017; ENSG00000056345; Homo sapiens. [Genome view]

GeneID

3690.

KEGG

hsa:3690.

UCSC

uc002ilj.1. human.

Organism-specific databases

CTD

3690.

GeneCards

GC17P042686.

H-InvDB

HIX0039255.

HGNC

HGNC:6156. ITGB3.

HPA

CAB002501.

MIM

173470. gene+phenotype.
273800. phenotype.

Orphanet

849. Glanzmann thrombasthenia.
140957. Macrothrombocytopenia with abnormal proplatelet formation, autosomal dominant.

PharmGKB

PA205.

GenAtlas

Search...

Phylogenomic databases

eggNOG

prNOG13368.

HOVERGEN

HBG006190.

InParanoid

P05106.

OMA

MKDDLWS.

OrthoDB

EOG9SJ80B.

PhylomeDB

P05106.

Enzyme and pathway databases

Pathway_Interaction_DB

arf6cyclingpathway. Arf6 signaling events.
ephrinbrevpathway. Ephrin B reverse signaling.
il4_2pathway. IL4-mediated signaling events.
avb3_integrin_pathway. Integrins in angiogenesis.
avb3_opn_pathway. Osteopontin-mediated events.
s1p_s1p1_pathway. S1P1 pathway.
s1p_s1p3_pathway. S1P3 pathway.
ptp1bpathway. Signaling events mediated by PTP1B.
vegfr1_2_pathway. Signaling events mediated by VEGFR1 and VEGFR2.

Reactome

REACT_13552. Integrin cell surface interactions.
REACT_604. Hemostasis.
REACT_6900. Signaling in Immune system.

Gene expression databases

ArrayExpress

P05106.

Bgee

P05106.

CleanEx

HS_ITGB3.

Genevestigator

P05106.

GermOnline

ENSG00000056345. Homo sapiens.

Family and domain databases

InterPro

IPR015812. Integrin_bsu.
IPR015435. Integrin_bsu-3_C.
IPR001169. Integrin_bsu_C.
IPR014836. Integrin_bsu_cyt.
IPR002369. Integrin_bsu_N.
IPR012012. Integrin_bsu_subgr.
IPR012896. Integrin_bsu_tail.
IPR003659. Plexin-like.
IPR002035. VWF_A.
[Graphical view]

Gene3D

G3DSA:1.20.5.630. Integrin_bsu_cyt. 1 hit.

PANTHER

PTHR10082. Integrin_beta_C. 1 hit.
PTHR10082:SF10. Integrin_bsu-3_C. 1 hit.

Pfam

PF08725. Integrin_b_cyt. 1 hit.
PF07965. Integrin_B_tail. 1 hit.
PF00362. Integrin_beta. 1 hit.
[Graphical view]

PIRSF

PIRSF002512. Integrin_B. 1 hit.

PRINTS

PR01186. INTEGRINB.

SMART

SM00187. INB. 1 hit.
SM00423. PSI. 1 hit.
SM00327. VWA. 1 hit.
[Graphical view]

SUPFAM

SSF69687. Integrin_bsu_tail. 1 hit.

PROSITE

PS00022. EGF_1. 2 hits. Uncertain.
PS01186. EGF_2. 1 hit. Uncertain.
PS00243. INTEGRIN_BETA. 3 hits.
PS50234. VWFA. False negative.
[Graphical view]

ProtoNet

Search...

Other Resources

DrugBank

DB00054. Abciximab.
DB00775. Tirofiban.

NextBio

14453.

PMAP-CutDB

P05106.

SOURCE

Search...

Entry information

Entry name

ITB3_HUMAN

Accession

Primary (citable) accession number: P05106
Secondary accession number(s): A0PJW2 , O15495, Q12806, Q13413, Q14648, Q16499

Entry history

Integrated into UniProtKB/Swiss-Prot:	August 13, 1987
Last sequence update:	February 6, 2007
Last modified:	March 2, 2010
This is version 155 of the entry and version 2 of the sequence. [Complete history]

Entry status

Reviewed (UniProtKB/Swiss-Prot)

Annotation project

HPI (Human Proteome Initiative)

Disclaimer

Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care.